Relationship between circulating microparticles and hypertension and other cardiac disease biomarkers in the elderly.
Age Factors
Aged
Aged, 80 and over
Aging
/ blood
Biomarkers
/ blood
Blood Platelets
/ metabolism
Blood Pressure
Case-Control Studies
Cell-Derived Microparticles
/ metabolism
Cross-Sectional Studies
Endothelium, Vascular
/ metabolism
Female
Heart Diseases
/ blood
Hemostasis
Humans
Hypertension
/ blood
Inflammation Mediators
/ blood
Male
Prognosis
Risk Assessment
Risk Factors
Endothelial dysfunction
Hypertension in the elderly
Microparticles
Procoagulant activity
Thrombin generation test
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
09 07 2019
09 07 2019
Historique:
received:
04
12
2018
accepted:
04
07
2019
entrez:
11
7
2019
pubmed:
11
7
2019
medline:
19
5
2020
Statut:
epublish
Résumé
Microparticles are procoagulant membrane vesicles that play role in endothelium dysfunction pathogenesis and are increased in hypertension, acute/chronic vascular pathological events. Here; we aimed to compare MPs levels of hypertensive geriatric patients with healthy age-match-patients, discuss its availability as a cardiovascular biomarker and investigate its relationship with other inflammatory markers. Forty seven hypertensive geriatric patients (M/F;15/32) and 47 healthy controls (M/F;19/28) were included in the study. MPs levels were examined functionally through thrombin generation test (TGT) parameters (MPS Lag time, MPS ETP, MPs Peak, MPS start Tail) and compared with CRP, N/L ratio, ALT, GGT, thrombocyte parameters. Decrease in MPS Lag time, increase in MPS ETS and MPs Peak elevation were accepted as tendency to coagulation which meant an increase in number and function of MPs. No significant difference was found between 2 groups for MPS tests (MPS Lag time, MPS ETP, MPs Peak, MPS start Tail). Platelet count was significantly higher in hypertensive patient group. There was a negative correlation between age and MPs Peak, MPS Lag time. There was a positive correlation between CRP and MPS ETP, MPs Peak values. Our present findings might help to understand the hemostasis via TGT parameters, in the elderly. Contribution of MPs to thrombosis tendency seen with aging and increased number of circulating MPs caused by hypertensive endothelial dysfunction must be taken into consideration. MPs might be accepted as vascular inflammation and damage markers and used as follow up tools of medical treatment of vascular inflammation-related diseases.
Sections du résumé
BACKGROUND
Microparticles are procoagulant membrane vesicles that play role in endothelium dysfunction pathogenesis and are increased in hypertension, acute/chronic vascular pathological events. Here; we aimed to compare MPs levels of hypertensive geriatric patients with healthy age-match-patients, discuss its availability as a cardiovascular biomarker and investigate its relationship with other inflammatory markers.
METHODS
Forty seven hypertensive geriatric patients (M/F;15/32) and 47 healthy controls (M/F;19/28) were included in the study. MPs levels were examined functionally through thrombin generation test (TGT) parameters (MPS Lag time, MPS ETP, MPs Peak, MPS start Tail) and compared with CRP, N/L ratio, ALT, GGT, thrombocyte parameters. Decrease in MPS Lag time, increase in MPS ETS and MPs Peak elevation were accepted as tendency to coagulation which meant an increase in number and function of MPs.
RESULTS
No significant difference was found between 2 groups for MPS tests (MPS Lag time, MPS ETP, MPs Peak, MPS start Tail). Platelet count was significantly higher in hypertensive patient group. There was a negative correlation between age and MPs Peak, MPS Lag time. There was a positive correlation between CRP and MPS ETP, MPs Peak values.
CONCLUSIONS
Our present findings might help to understand the hemostasis via TGT parameters, in the elderly. Contribution of MPs to thrombosis tendency seen with aging and increased number of circulating MPs caused by hypertensive endothelial dysfunction must be taken into consideration. MPs might be accepted as vascular inflammation and damage markers and used as follow up tools of medical treatment of vascular inflammation-related diseases.
Identifiants
pubmed: 31288734
doi: 10.1186/s12872-019-1148-6
pii: 10.1186/s12872-019-1148-6
pmc: PMC6617697
doi:
Substances chimiques
Biomarkers
0
Inflammation Mediators
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
164Références
Am J Physiol Heart Circ Physiol. 2004 May;286(5):H1910-5
pubmed: 15072974
Am J Physiol. 1994 Jul;267(1 Pt 2):R136-43
pubmed: 8048615
Curr Hypertens Rep. 2011 Aug;13(4):276-81
pubmed: 21499710
J Atheroscler Thromb. 2016;23(1):1-9
pubmed: 26412494
Diabetes Res Clin Pract. 2005 Jun;68(3):193-201
pubmed: 15936460
J Gerontol A Biol Sci Med Sci. 2010 Apr;65(4):414-20
pubmed: 19942591
PLoS One. 2014 Jan 08;9(1):e85465
pubmed: 24416412
J Thromb Thrombolysis. 2004 Dec;18(3):177-85
pubmed: 15815879
Ann Neurol. 2009 Aug;66(2):191-9
pubmed: 19743467
Circulation. 2004 Apr 6;109(13):1653-9
pubmed: 15023873
Semin Thromb Hemost. 2002 Dec;28(6):555-68
pubmed: 12536349
J Am Coll Cardiol. 1994 Aug;24(2):471-6
pubmed: 8034885
Circulation. 2001 Nov 27;104(22):2649-52
pubmed: 11723013
J Stroke Cerebrovasc Dis. 2015 Oct;24(10):2313-20
pubmed: 26169549
Acta Pharmacol Sin. 2014 Apr;35(4):433-43
pubmed: 24608676
Semin Thromb Hemost. 2008 Oct;34(7):670-82
pubmed: 19085768
N Engl J Med. 2003 Feb 13;348(7):593-600
pubmed: 12584367
Exp Gerontol. 2008 Feb;43(2):66-73
pubmed: 17869046
Am Heart J. 2003 Jun;145(6):962-70
pubmed: 12796750
Crit Rev Oncol Hematol. 2006 Nov;60(2):144-51
pubmed: 16860994
Hypertension. 1987 Jun;9(6 Pt 2):III193-7
pubmed: 3596786
Hypertension. 2003 Feb;41(2):211-7
pubmed: 12574084
Semin Thromb Hemost. 2009 Feb;35(1):104-10
pubmed: 19308898
J Am Coll Cardiol. 2005 May 17;45(10):1622-30
pubmed: 15893178
Arterioscler Thromb Vasc Biol. 2011 Aug;31(8):1898-907
pubmed: 21597004
Front Biosci. 2003 Sep 01;8:s1199-209
pubmed: 12957863
J Intensive Care. 2015 Jan 07;3(1):2
pubmed: 25705427
Thromb Res. 2006;117(4):385-92
pubmed: 15896827
J Thromb Haemost. 2004 Oct;2(10):1842-51
pubmed: 15456497
Int J Hypertens. 2012;2012:150107
pubmed: 22046504
Arteriosclerosis. 1987 Jan-Feb;7(1):88-100
pubmed: 3813979
Thromb Res. 2013 Apr;131(4):e168-74
pubmed: 23414567
Thromb Res. 2011 Feb;127 Suppl 3:S21-5
pubmed: 21262433
J Thromb Haemost. 2010 Nov;8(11):2571-4
pubmed: 20831623
Semin Thromb Hemost. 2014 Sep;40(6):621-33
pubmed: 25099191
Am J Respir Crit Care Med. 2008 Mar 1;177(5):536-43
pubmed: 18006886
Rev Bras Hematol Hemoter. 2017 Jul - Sep;39(3):259-265
pubmed: 28830606
J Am Coll Cardiol. 2005 May 3;45(9):1441-8
pubmed: 15862416
Am J Hypertens. 2004 Sep;17(9):757-63
pubmed: 15363816
Maturitas. 2011 Aug;69(4):373-6
pubmed: 21641736
Thromb Res. 2008;123(1):8-23
pubmed: 18667228
Blood Rev. 2013 Jan;27(1):31-9
pubmed: 23261067
J Thromb Haemost. 2010 Nov;8(11):2358-68
pubmed: 20695980
Clin Exp Immunol. 2000 Sep;121(3):437-43
pubmed: 10971508
Age Ageing. 2003 Nov;32(6):661-5
pubmed: 14600009